Patients Stopping Anti-Obesity Medications Put On Weight Far More Rapidly Compared to People Using Diet and Exercise

A recent study indicates that individuals who come off new slimming jabs like Wegovy and Mounjaro may regain lost weight far faster than those who stop conventional lifestyle programs.

Research printed in a leading health publication shows that while overweight people can lose a large proportion of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.

"Users using such medications should be cognizant of the danger of quick rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.

That rate of regain means a reversion to pre-treatment mass within about a year and a half.

Analyzing Approaches

The study, which looked at dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.

Scientists point out that people who shed pounds through dieting generally have a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.

Understanding the Quick Regain

Nutrition scientists suggest the way of the drugs accounts for the accelerated rebound.

The injections mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Artificially providing the hormone levels far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this medication leads to appetite is uncontrolled, making overeating far more likely."

An Ongoing Condition?

The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.

Professionals say that, due to the significant potential of relapse, the treatment is often ongoing.

This opinion is supported by pharmaceutical companies, who state that the findings "highlight the persistent nature of excess weight," akin to managing diseases like diabetes.

User Experiences

People who have discontinued the medication report a sudden resurgence of hunger.

"I experienced a trigger flipping and you become ravenous," said one woman.

This difficulty is worsened if patients have not established lasting lifestyle or habit changes during therapy.

Significant Interest

Figures show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.

• Adoption is more common among females than males.
• The middle-aged age group shows the highest usage rates.
• A large proportion access the medications through private prescriptions rather than public health services.

Ultimately, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and long-term success likely depends on combined behavioural management.